


**Supplemental Table S1: *Staphylococcus aureus* strains**

<b>Strain</b>	<b>Genotypes or characteristics</b>	<b>Colony color</b>	<b>Resource or reference</b>
LAC13C	USA300, SCC <i>mecIV</i> , pvl <sup>+</sup>	Yellow	(9)
LACJE2	USA300, SCC <i>mecIV</i> , pvl <sup>+</sup>	Yellow	(9)
BAA 1695	(Non USA100 – 1100) MRSA, pvl <sup>-</sup>	White	ATCC
MW2	USA400, MRSA	Yellow	ATCC
NEWMAN	MSSA	Yellow	ATCC
BAA 1692	USA100 SCC <i>mecII</i> , Agr type II, pvl <sup>-</sup>	White	ATCC
BAA 1750	USA200, pvl <sup>-</sup>	White	ATCC
BAA 1760	USA200, pvl <sup>-</sup>	White	ATCC
BAA 15565	MSSA	Cream	ATCC
BAA 29213	MSSA	White	ATCC
BAA 1556	USA300, SCC <i>mecIV</i> , pvl <sup>+</sup>	Cream	ATCC
BAA 1696	USA400, SCC <i>mecIV</i> , pvl <sup>+</sup>	Yellow	ATCC
HFH-30522	USA500, SCC <i>mecIV</i> , pvl <sup>-</sup>	Cream	BEI
NRS70/N315	USA100, SCC <i>mecII</i> , pvl <sup>-</sup>	Yellow	BEI
NRS668	USA800, SCC <i>mecIV</i> , pvl <sup>-</sup>	Cream	BEI
NRS689	USA700, SCC <i>mecIV</i> , pvl <sup>-</sup>	Gray	BEI
NRS715	USA600, SCC <i>mecIV</i> , pvl <sup>-</sup>	Gray	BEI
NRS 484	USA1100, SCC <i>mecIV</i> , pvl <sup>+</sup>	Cream	BEI
NRS 155 (502AΔ <i>agr</i> )	MSSA	Gray	BEI
502A	MSSA	Gray	(20)
NRS 385	USA500, SCC <i>mecIV</i> , pvl <sup>-</sup>	Yellow	BEI
NRS 686	USA500, SCC <i>mecIV</i> , pvl <sup>-</sup>	Yellow	BEI
NRS 483	USA1000, SCC <i>mecIV</i> , pvl <sup>+</sup> , enterotoxin B <sup>+</sup>	Yellow	BEI

**Supplemental Table S2: Mutant strains**

<b>Strain Number</b>	<b>Gene Symbol</b>	<b>Gene Disrupted</b>	<b>Resource or reference</b>
NE1354	<i>hla</i>	Alpha-hemolysin precursor (41, 42)	(9)
NE1532	<i>agrA</i>	Accessory gene regulator protein A (43, 44)	(9)
NE1787	<i>srtA</i>	Sortase (45, 46)	(9)
NE1366	<i>kata</i>	Catalase (47)	(9)
NE1444	<i>crtM</i>	Squalene desaturase (12, 13)	(9)
NE1929	<i>dps</i>	General stress protein 20U (48)	(9)
NE1848	<i>pvl</i>	Panton-Valentine leukocidin, LukS-PV (49, 50)	(9)
NE518	<i>crtQ</i>	4,4'-diaponeurosporenoate glycosyl transferase	(9)
NE1224	<i>sod</i>	Fe/Mn family superoxide dismutase (51)	(9)
NE1622	<i>saeR</i>	Response regulator SaeR (52, 53)	(9)
NE1684	<i>arlR</i>	Response regulator arlR (54)	(9)
NE1193	<i>sarA</i>	Staphylococcal accessory regulator A (55)	(9)
NE543	<i>clfA</i>	Clumping Factor A (56, 57)	(9)
NE302	<i>cap5a</i>	Capsular polysaccharide biosynthesis protein Cap5A (58, 59)	(9)
NE295	<i>adsA</i>	Adenosine synthase A (60)	(9)
NE911	<i>ahpC</i>	Alkyl hydroperoxide reductase subunit C (47)	(9)
NE1373	<i>oatA</i>	O-acetyltransferase (61)	(9)
LAC13C $\Delta$ <i>psm</i>	<i>psm</i>	Phenol soluble modulins (55)	(16)
LAC13C <i>spa:kan</i>	<i>spa</i>	Surface protein A	(62)





**Supplemental Figure S1. The pathogenic success of prevalent CA-MRSA strains is not associated with their lethality in mice.** (A) Survival of C57BL/6 mice after intranasal (i.n.) infection with high doses of LAC-JE2 (LAC), MW2 or BAA-1695. Data shown were combined from two independent experiments. (B) Numbers of bacteria remaining in the lungs 5 and 18 h after i.n. infection with  $5 \times 10^8$  CFU/mouse *S. aureus*. Data shown are representative of two independent experiments.

**A**

Time (min)	-lysostaphin (cfu/100 MHS)	+lysostaphin (cfu/100 MHS)
0	510	0
60	770	860

**B**

Time (min)	-lysostaphin (cfu/100 MHS)	+lysostaphin (cfu/100 MHS)
0	530	3
60	520	540

**C****D**

**Supplemental Figure S2. Alveolar macrophages are efficient in *S. aureus* uptake.** Numbers of (A) GFP-LAC-JE2 and (B) GFP-1695 associated with MH-S cells, and (C-D) kinetics of GFP-LAC-JE2 (GFP-LAC) (C) and GFP-1695 (D) internalization by MH-S cells at 37°C. MH-S cells were inoculated with *S. aureus* at MOI 10 and co-incubated for 60 min on ice, allowing bacteria binding onto the cells, before further incubation at 37°C. At various time points, i.e., 0, 20, 40, and 60 min, extracellular bacteria were lysed by adding 20ug/ml of lysostaphin and incubating the cell cultures for 10 min at 37 °C. Data shown are representative of two independent experiments.